Search

Developing strategies aimed to shorten the length of stay (LOS) in patients with ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI) is a healthcare goal to be pursued. We carried out a sub-analysis of the GSH 2014 trial to assess the potentiality of glutathione sodium salt infusion to impact on LOS.100 consecutive patients with STEMI, aged more than 18 years and referred to the three enrolling centers for primary angioplasty (p-PCI), were asked to participate to the GSH 2014 trial. Fifty patients were randomized to treatment group and fifty to placebo; treatment consisted into an intravenous infusion of gluthatione sodium salt over 10 min before p-PCI; after interventions, glutathione was infused at the same doses at 24, 48 and 72 h elapsing time. A stepwise linear multivariate model was built in order to assess independent predictors of LOS.Subjects receiving infusion of glutathione sodium salt had a significantly lower LOS than subjects receiving placebo (8.6±3 vs 10.8±4 days, p=0.006). At multivariate analysis, the randomization to GSH group was negatively associated with length of stay (β±SEβ -1.64±0.74, cumulative R2 0.43, p=0.03) independently from age, sex, cardiovascular risk factors, number of treated vessels, infarct-related coronary artery (left anterior descending artery as reference) and enrolment hospital.Results from this sub-analysis support the hypothesis that an early and prolonged glutathione sodium salt administration, as antioxidant therapy to patients with STEMI, may favorably impact on LOS. Further studies with larger sample size are necessary to confirm these data.